Application of a Topical Biomimetic Electrical Signaling Technology to Photo-Aging: A Randomized, Double-Blind, Placebo-Controlled Trial of a Galvanic Zinc-Copper Complex

被引:0
|
作者
Chantalat, Jeannette [1 ]
Bruning, Elizabeth [1 ]
Sun, Ying [1 ]
Liu, Jue-Chen [1 ]
机构
[1] Johnson & Johnson Consumer Prod Co, Skillman, NJ USA
关键词
TRETINOIN; SKIN; STIMULATION; THERAPY; WOUNDS;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The first signs of facial skin photo-aging often occur in the skin of the periorbital area and include sagging, loss of firmness and definition, and sallowness. Epidermal wounds have been shown to alter the trans-epithelial electrical potential creating an electric signal that directs cell migration in epithelial wound healing; this electric field declines sharply with age. A topical galvanic zinc-copper complex, which couples elemental zinc and copper to create a biomimetic electric field, has demonstrated anti-inflammatory activity and extracellular matrix improvement in vitro, including collagen and elastin production. Objectives: To evaluate the efficacy and tolerability of a galvanic zinc-copper complex on photo-aging parameters in a randomized, double-blind, placebo-controlled clinical trial. Materials and Methods: In this eight-week study, women 140-65 years) with mild to moderate photo-aging were randomized to use placebo or 1 of 3 galvanic zinc-copper complex compositions (gel and activating moisturizer). Efficacy evaluations included clinical grading, specialized clinical imaging, and subject self-assessments performed at baseline, 15-30 minutes after product application and after 1, 2, 4, and 8 weeks.Tolerability was based on adverse events and clinical grading of irritation. Significance was set at P <= 0.05 versus baseline and between treatment groups. Results: The study was completed by 124 women. Compositions containing the galvanic zinc-copper complex showed statistically significant clinical improvements versus placebo and baseline rapidly (15-30 min) after application and through week 8. Clinical grading showed significant improvement versus placebo in skin radiance and under-eye dark circles 15-30 minutes after first application with continued improvement through week 8, and in overall photo-damage, fine lines, lifted appearance of the eyes, and under-eye wrinkles starting after two weeks and continuing through week 8. Test compositions were well tolerated. Conclusion:This galvanic zinc-copper complex provided rapid and lasting improvements versus placebo in photo-aged skin, supporting its use in topical anti-aging formulations.
引用
收藏
页码:30 / 37
页数:8
相关论文
共 50 条
  • [21] Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial
    Tepper, Stewart J.
    Rabany, Liron
    Cowan, Robert P.
    Smith, Timothy R.
    Grosberg, Brian M.
    Torphy, Bradley D.
    Harris, Dagan
    Vizel, Maya
    Ironi, Alon
    Stark-Inbar, Alit
    Blumenfeld, Andrew M.
    HEADACHE, 2023, 63 (03): : 377 - 389
  • [22] A randomized, double-blind, placebo-controlled trial: Paroxetine controlled release in fibromyalgia
    Patkar, AA
    Masand, PS
    Jiang, W
    Krulewicz, S
    Dube, E
    Purcell, C
    McMorran, C
    Peindl, K
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S319 - S320
  • [23] A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
    Turner, R. Scott
    Thomas, Ronald G.
    Craft, Suzanne
    van Dyck, Christopher H.
    Mintzer, Jacobo
    Reynolds, Brigid A.
    Brewer, James B.
    Rissman, Robert A.
    Raman, Rema
    Aisen, Paul S.
    NEUROLOGY, 2015, 85 (16) : 1383 - 1391
  • [24] Lansoprazole in Globus Pharyngeus: Double-Blind, Randomized, Placebo-Controlled Trial
    Dumper, Jaymi
    Mechor, Brad
    Chau, Jason
    Allegretto, Michael
    JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2008, 37 (05): : 657 - 663
  • [25] Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial
    Levin, B
    Thompson, JLP
    Levy, G
    Mitsumoto, H
    Kaufmann, P
    NEUROLOGY, 2006, 66 (11) : 1786 - 1786
  • [26] Alendronate in primary hyperparathyroidism: A double-blind, randomized, placebo-controlled trial
    Khan, AA
    Bilezikian, JP
    Kung, AWC
    Ahmed, MM
    Dubois, SJ
    Ho, AYY
    Schussheim, D
    Rubin, MR
    Shaikh, AM
    Silverberg, SJ
    Standish, TI
    Syed, Z
    Syed, ZA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (07): : 3319 - 3325
  • [27] DEXAMETHASONE FOR THE TREATMENT OF DEPRESSION - A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL
    ARANA, GW
    SANTOS, AB
    LARAIA, MT
    MCLEODBRYANT, S
    BEALE, MD
    RAMES, LJ
    ROBERTS, JM
    DIAS, JK
    MOLLOY, M
    AMERICAN JOURNAL OF PSYCHIATRY, 1995, 152 (02): : 265 - 267
  • [28] Donepezil for cancer fatigue: A double-blind, randomized, placebo-controlled trial
    Bruera, Eduardo
    El Osta, Badi
    Valero, Vicente
    Driver, Larry C.
    Pei, Be-Lian
    Shen, Loren
    Poulter, Valerie A.
    Palmer, J. Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3475 - 3481
  • [29] Fluoxetine for depression in diabetes - A randomized double-blind placebo-controlled trial
    Lustman, PJ
    Freedland, KE
    Griffith, LS
    Clouse, RE
    DIABETES CARE, 2000, 23 (05) : 618 - 623
  • [30] Creatine Supplementation in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial
    Alves, Christiano R. R.
    Santiago, Bianca M.
    Lima, Fernanda R.
    Otaduy, Maria C. G.
    Calich, Ana Luisa
    Tritto, Aline C. C.
    de Sa Pinto, Ana Lucia
    Roschel, Hamilton
    Leite, Claudia C.
    Benatti, Fabiana B.
    Bonfa, Eloisa
    Gualano, Bruno
    ARTHRITIS CARE & RESEARCH, 2013, 65 (09) : 1449 - 1459